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Cell fate decisions of pluripotent embryonic stem
(ES) cells are dictated by activation and repression
of lineage-specific genes. Numerous signaling and
transcriptional networks progressively narrow and
specify the potential of ES cells. Whether specific
microRNAs help refine and limit gene expression
and, thereby, could be used tomanipulate ES cell dif-
ferentiation has largely been unexplored. Here, we
show that two serum response factor (SRF)-depen-
dent muscle-specific microRNAs, miR-1 and miR-
133, promote mesoderm formation from ES cells
but have opposing functions during further differen-
tiation into cardiac muscle progenitors. Furthermore,
miR-1 and miR-133 were potent repressors of non-
muscle gene expression and cell fate during mouse
and human ES cell differentiation. miR-1’s effects
were in part mediated by translational repression of
the Notch ligand Delta-like 1 (Dll-1). Our findings indi-
cate that muscle-specific miRNAs reinforce the
silencing of nonmuscle genes during cell lineage
commitment and suggest that miRNAs may have
general utility in regulating cell-fate decisions from
pluripotent ES cells.
INTRODUCTION
Embryonic stem (ES) cells, derived from the inner cell mass of
blastocysts, are pluripotent and self-renewing cells with the
unique ability to give rise to all three germ layers—ectoderm, me-
soderm, and endoderm. Precise regulation of cell-fate decisions
is a prerequisite for future therapeutic use of ES cells. Numerous
signaling pathways, including those involving members of the
Wnt, Bmp, and Notch pathways, appear to regulate cell fate dur-
ing embryogenesis and can be utilized in various forms to influ-
ence lineage choices in cultured ES cells (reviewed in Loebelet al., 2003). Such pathways often culminate in transcriptional
events, through either DNA-binding proteins or chromatin-re-
modeling factors that dictate which subset of the genome is ac-
tivated or silenced in specific cell types. As a result, transcription
factors that regulate pluripotency or lineage-specific gene and
protein expression have been a major focus of ES cell research.
In addition to transcriptional regulation, posttranscriptional
control by small noncoding RNAs, such as microRNAs (miRNAs),
quantitatively influences the ultimate proteome (He and Hannon,
2004; Ambros, 2004). miRNAs are naturally occurring RNAs that
are transcribed in the nucleus, often under the control of specific
enhancers, and are processed by the RNases Drosha/DGCR8
and Dicer into mature 22 nucleotide RNAs that bind to com-
plementary target mRNAs. miRNA:mRNA interactions in RNA-
induced silencing complexes can result in mRNA degradation,
deadenylation, or translational repression at the level of the ribo-
some. Over 450 human miRNAs have been described, and each
is predicted to target tens if not hundreds of different mRNAs.
Because they can regulate numerous genes, often in common
pathways, miRNAs are candidates for master regulators of cellu-
lar processes, much like transcription factors that regulate entire
programs of cellular differentiation and organogenesis (Zhao
and Srivastava, 2007).
As pluripotent cells adopt particular fates, genes are transcrip-
tionally activated that specify lineages. For ES-derived cell
types, it is equally critical to suppress the expression of genes
that would otherwise drive differentiation toward alternative
fates. While this occurs at the transcriptional level, it is possible
that miRNAs also contribute to this process by clearing latently
expressed mRNAs as cells activate expression profiles reflecting
their newly adopted fates. Indeed, ES cells lacking Dicer or Dro-
sha, and therefore most mature miRNAs, cannot differentiate
into most lineages (Kanellopoulou et al., 2005; Murchison
et al., 2005; Wang et al., 2007). Although ES cell-specific miRNAs
have been described (Houbaviy et al., 2003), the function or po-
tential of specific miRNAs in ES cell differentiation has not been
reported.
During differentiation of ES cells into aggregates called embry-
oid bodies (EBs), which to a limited extent recapitulate embry-
onic development, cardiomyocytes are among the first cell typesCell Stem Cell 2, 219–229, March 2008 ª2008 Elsevier Inc. 219
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small clusters of rhythmically and synchronously contracting
cells. Like naturally occurring cardiac muscle cells, ES cell-de-
rived cardiomyocytes express markers of cardiac differentiation,
assemble contractile machinery, and establish cell-cell commu-
nication (Maltsev et al., 1994).
In addition to the numerous transcription factors and signaling
molecules that control development of cardiac cells (Srivastava,
2006), miRNAs have a critical role in cardiac differentiation in vivo
(Zhao et al., 2005; Kwon et al., 2005; Zhao et al., 2007). In partic-
ular, miR-1 and miR-133 are cardiac and skeletal muscle-spe-
cific, bicistronic miRNAs that are transcriptionally controlled by
some of the major regulators of muscle differentiation: serum re-
sponse factor (SRF), MyoD, and Mef2 (Zhao et al., 2005; Kwon
et al., 2005; Sokol and Ambros, 2005; Rao et al., 2006). miR-1
promotes differentiation of cardiac progenitors and exit from
the cell cycle in mammals and in flies (Zhao et al., 2005, 2007;
Kwon et al., 2005). In contrast, miR-133 inhibits differentiation
of skeletal myoblasts and maintains them in a proliferative state
(Chen et al., 2006). Several direct targets of miR-1 have been de-
scribed in vivo (Zhao et al., 2005; 2007), including Hand2, a tran-
scription factor required for expansion of cardiac progenitors
(Srivastava et al., 1997; Yamagishi et al., 2001), and the Notch
ligand delta in Drosophila (Kwon et al., 2005).
Here, we show that miR-1 and miR-133 are enriched in ES cell-
derived cardiomyocytes and are expressed at the early stages of
cardiac mesoderm selection from ES cells. Expression of either
miR-1 or miR-133 in ES cells resulted in enhanced mesoderm
gene expression in differentiating EBs but suppressed differenti-
ation into the ectodermal or endodermal lineages. However,
miR-1 and miR-133 had opposing effects on further adoption
of muscle lineages, with miR-1 promoting and miR-133 blocking
differentiation into either cardiac or skeletal muscle fates. Delta-
like 1 (Dll-1), a Notch ligand expressed in ES cells, was transla-
tionally repressed in miR-1-expressing ES cells, and depletion
of Dll-1 from ES cells resulted in a bias toward the cardiac lineage
while suppressing endoderm and neuroectoderm differentiation,
similar to miR-1-expressing ES cells. Our findings demonstrate
that miRNAs can control cell lineage determination from pluripo-
tent ES cells, likely by fine-tuning the transcriptome of differenti-
ating cells during commitment to a newly adopted fate.
RESULTS
miRNA Expression in Mouse ES Cells and ES
Cell-Derived Cardiomyocytes
To determine which miRNAs are enriched during differentiation
of mouse ES (mES) cells into cardiomyocytes, we used a mES
cell line carrying a green fluorescent protein (GFP) transgene un-
der control of the b-myosin heavy-chain promoter, which is
uniquely expressed in differentiated cardiomyocytes. We iso-
lated RNA from GFP+ and GFP– cells by fluorescence-activated
cell sorting after 13 days of EB differentiation and profiled miRNA
expression by microarray analysis. Seventeen miRNAs were en-
riched at least 3-fold in the GFP+ population (Figure 1A). Approx-
imately half of the miRNAs that were enriched in mES cell-
derived cardiomyocytes, including the muscle-specific miRNAs
miR-1 and miR-133, were undetectable in undifferentiated mES220 Cell Stem Cell 2, 219–229, March 2008 ª2008 Elsevier Inc.cells, indicating that they were unique to differentiating cells
(Figure 1A).
To determine whether miR-1 and miR-133 were present and
enriched in early cardiac progenitors, we utilized a mES cell
line carrying a GFP transgene under transcriptional control of
a recombinant bacterial artificial chromosome containing the
Nkx2.5 enhancer (B.R.C., Y. Yoshinaga, T.D. Nguyen, S.L. Mu-
sone, J.E. Kim, P. Swinton, I. Espineda, C. Manalac, P.J. deJong,
and E.C.H., unpublished data). This line effectively marks the
early emergence of precardiac mesoderm. Sorting of GFP-pos-
itive cells in day 4 EBs followed by quantitative RT-PCR (qRT-
PCR) revealed that the muscle-specific miRNAs were expressed
Figure 1. Identification of miRNAs Expressed in ES Cell-Derived
Cardiomyocytes
(A) mES cells carrying a GFP transgene under control of the cardiomyocyte-
specific b-myosin heavy chain promoter were differentiated for 13 days as
embryoid bodies (EBs), sorted by GFP expression, and analyzed by miRNA
microarray. miRNAs enriched at least threefold in the GFP+ compared to
GFP– cell populations are listed along with their fold enrichment and whether
they were detected in ES cells.
(B and C) Quantitative RT-PCR (qRT-PCR) showing enrichment of miR-1 and
miR-133 in flow-sorted Nkx2.5-GFP+ cardiac progenitors from day 4 EBs (B),
but not in Flk-1+ vascular progenitors, which are enriched in the endothelial-
specific miRNA, miR-126 (C).
(D) qRT-PCR showing expression kinetics of miR-1 and miR-133 during days
4–10 of EB differentiation.
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(Figure 1B), while the vascular endothelium-enriched miRNA,
miR-126, was absent (Kuehbacher et al., 2007). Conversely,
when we sorted vascular progenitors from day 4 EBs based on
their cell surface expression of Flk-1, miR-1 and miR-133 were
absent from the Flk-1+ mesoderm population in which miR-126
was highly expressed (Figure 1C). We also examined the kinetics
of miR-1/miR-133 expression in differentiating whole EBs
(Figure 1D). Both were detectable as early as day 4, and their
expression increased until day 6, after which their relative abun-
dance in the growing EBs diminished and other cell types
emerged.
miR-1 and miR-133 Can Promote Mesoderm
Differentiation in mES Cells
Since miR-1 and miR-133 were not expressed in undifferentiated
mES cells but were specifically enriched in precardiac meso-
derm, we hypothesized that their introduction into mES cells
might bias cells toward a muscle lineage. Lentiviruses were
used to infect and select ES cell lines expressing miR-1
(mESmiR-1) or miR-133 (mESmiR-133) (Figure 2A). The levels of intro-
duced miRNAs approximated those of the endogenous miRNAs
in the mouse heart (Figure 2B). The morphology (data not shown)
and doubling time of the cell lines in LIF-containing medium were
unaltered (Figure 2C), and the pluripotency markers Oct-4 and
Nanog were expressed at normal levels (data not shown).
To assess the lineage potential of mES cells expressing miR-1
and miR-133,we differentiated control, mESmiR-1, and mESmiR-133
cells by the hanging drop method; collected the resulting EBs on
days 4, 6, and 10 of differentiation; and examined the expression
of lineage markers by qRT-PCR. Since miR-1 and miR-133 were
normally expressed in day 4 precardiac mesoderm, we exam-
ined expression of the early mesoderm marker, Brachyury
(Bry). Bry expression was detected transiently in control EBs at
day 4 and then rapidly declined (Figure 2D and data not shown).
In day 4 EBs expressing miR-1 or miR-133, Bry expression was
dramatically enhanced (Figure 2D), suggesting that both can
promote mesodermal gene expression in pluripotent mES cells.
To determine the effects of miR-1 and miR-133 on further dif-
ferentiation, we examined expression of Nkx2.5, a transcription
factor that is one of the earliest cardiac markers (Figure 2E). In
control EBs, Nkx2.5 expression was detected by day 6 and
was maintained at day 10. Expression of miR-1 increased
Nkx2.5 expression at day 6; by day 10, it was 7-fold greater
than in control EBs. Strikingly, expression of miR-133 blocked in-
duction ofNkx2.5 at both time points. We performed a similar ex-
pression analysis of Myogenin, an early skeletal muscle marker,
to determine the effects of miR-1 and miR-133 on skeletal mus-
cle differentiation. qRT-PCR analysis of Myogenin expression in
day 4, 6, or 10 EBs revealed that miR-1, but not miR-133, mark-
edly enhanced Myogenin expression (Figure 2F).
The increase in Nkx2.5 expression, as assessed by qRT-PCR,
may represent either an increase in the amount of Nkx2.5 ex-
pressed per cell or in the number of cells expressing Nkx2.5.
To distinguish between these two possibilities, we infected the
Nkx2.5-GFP mES line with control, miR-1-, or miR-133-express-
ing lentivirus; selected with antibiotic; and differentiated these
cells for 10 days. GFP was expressed in more miR-1-expressing
EBs, and at higher levels per cell, than in wild-type EBs, and wasalmost undetectable in miR-133-expressing cells (Figure 2G).
Thus, miR-1 appears to promote the emergence of both cardiac
and skeletal progenitors in mES cells, while miR-133 does not
enhance further differentiation of mesoderm precursors into
either lineage.
miR-1 or miR-133 Can Rescue Mesoderm Gene
Expression in SRF–/– EBs
Efficient methods for stable miRNA knockdown studies in differ-
entiating EBs are not yet available due to the rapid doubling time
of ES cells. However, we previously showed that expression of
the miR-1/miR-133 locus in embryonic mouse hearts is directly
dependent on SRF (Zhao et al., 2005). Therefore, we sought to
use SRF/ ES cells (Niu et al., 2005) as a model for complemen-
tation experiments that might reveal the specific contribution of
these miRNAs within SRF/ cells (Zhao et al., 2005). We found
that SRF/ EBs failed to activate miR-1 or miR-133 (Figure 2H),
confirming the SRF dependency in the ES cell system, consis-
tent with in vivo observations. Differentiation of mesodermal pro-
genitors in EBs lackingSRF is weak and delayed (Weinhold et al.,
2000). To our surprise, however, Bry expression persisted in
SRF/ EBs, even after 10 days of differentiation, reflecting de-
layed or arrested differentiation of mesodermal progenitors
that normally downregulate Bry by day 5 (Figure 2I). Despite
the many genes dysregulated in SRF/ EBs, reintroduction of
miR-1 in SRF/ ES cells rescued the abnormal accumulation
of Bry+ progenitors at day 10 of differentiation, with Bry levels
returning close to wild-type levels. Introduction of miR-133 had
an intermediate effect on the level of Bry expression at day 10,
but Bry levels were still significantly decreased. SRF/ ES cells
also displayed elevated expression of Mesp1, a marker of
nascent cardiac mesoderm that is usually downregulated as
differentiation progresses (Saga et al., 1996), and this was simi-
larly corrected by reintroduction of miR-1 or miR-133 (Figure 2I).
These data suggest miR-1 and, to a lesser degree, miR-133
can promote the progression of mesodermal progenitors and
that the arrest of mesodermal progenitors in the absence
of SRF may be largely due to the absence of this family of
miRNAs.
Consistent with the changes in Bry expression, expression of
miR-1 or miR-133 restored the expression of a number of meso-
dermal genes in day 10 SRF/ EBs (Figure 2J). Blood cell–spe-
cific genes, such as Cd53, CxCl4, and Thbs1, were dramatically
downregulated in SRF–/– EBs, reflecting the loss of hemato-
poeitic lineages in the absence of SRF. However, their expres-
sion was reinitiated upon reintroduction of miR-1 or miR-133,
likely representing relief of the block to mesodermal differentia-
tion. Even expression of Mef2c, a major regulator of muscle lin-
eages (Molkentin et al., 1995), was restored by miR-1 and, to
a lesser extent, by miR-133.
miR-1 and miR-133 Suppress Endoderm Differentiation
in mES Cells
It has been proposed that in some contexts miRNAs function in
a ‘‘fail-safe’’ mechanism to clear latent gene expression by tar-
geting pathways that should not be activated in a particular
cell type (Hornstein et al., 2005). Therefore, we investigated
whether miR-1 and miR-133 might not only promote muscle
lineage decisions but also reinforce them by repressingCell Stem Cell 2, 219–229, March 2008 ª2008 Elsevier Inc. 221
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(A) Schematic of methods used to express miRNAs in mES cells. mES cells were infected with lentiviruses expressing miR-1 or miR-133 under control of a
heterologous EF-1 promoter. Stably infected cells were selected based on their resistance to blasticidin to generate stable miRNA-expressing mES cell lines
(mESmiR-1 and mESmiR-133).
(B) qRT-PCR results confirmed the expression of miR-1 and miR-133; expression of the unintroduced miRNA was unchanged. miR-1 and miR-133 were ex-
pressed at levels comparable to those in the adult mouse heart. Error bars reflect one standard deviation.
(C) The population doubling times of mESmiR-1 and mESmiR-133 cells were similar to those of control cells. Error bars reflect one standard deviation.
(D) qRT-PCR analyzing expression of Bry, an early mesoderm marker, in control, mESmiR-1, and mESmiR-133 EBs collected on day 4 of differentiation. Expression
of miR-1 or miR-133 increased expression of Bry. Error bars reflect one standard deviation.
(E and F) qRT-PCR analysis of Nkx2.5 (E) and Myogenin (F) expression from day 4, 6, or 10 EBs formed from control, mESmiR-1, or mESmiR-133 cells. Control EBs
displayed an induction of Nkx2.5 expression over time that was enhanced by miR-1 and suppressed by miR-133. Induction of Myogenin expression was en-
hanced by miR-1, but not by miR-133. Error bars reflect one standard deviation.
(G) Differences in Nkx2.5 expression (green fluorescent cells) were also visualized at day 10 of differentiation by expressing the miRNAs in an Nkx2.5-GFP trans-
genic mES cell line.
(H) Expression of miR-1 and miR-133 was undetectable in day 10 SRF–/– EBs by qRT-PCR. Error bars reflect one standard deviation.
(I) Overexpression of miR-1 and, to a lesser extent, miR-133 in SRF–/– EBs restored the Bry and Mesp1 downregulation in day 10 EBs typical of wild-type cells.
(J) Expression of Cd53, Cxcl4, and Thbs1, which mark hematopoietic lineages, and of Mef2c, which encodes a major regulator of muscle differentiation, was
partially rescued in SRF/ EBs upon expression of miR-1 or miR-133.nonmuscle gene expression. First, we differentiated control,
mESmiR-1, and mESmiR-133 ES cells in the presence of recombi-
nant nodal, a potent inducer of endoderm differentiation in
mES cells (Vallier et al., 2004; Pfendler et al., 2005). As expected,
nodal stimulated expression of the endoderm markers a-Feto-
protein (Afp) andHnf4a in control EBs (Figures 3A and 3B). These
markers were expressed at dramatically lower levels in mESmiR-1
and mESmiR-133 EBs than in control EBs, indicating that miR-1 or
miR-133 can each function as potent repressors of endoderm
gene expression during differentiation of pluripotent mES cells
(Figures 3A and 3B).
miR-1 and miR-133 Suppress Neural Differentiation
from mES Cells
Next, we asked whether miR-1 or miR-133 could also suppress
neuroectoderm gene expression from pluripotent mES cells.
Control, mESmiR-1, and mESmiR-133 ES cells were differentiated
in the presence of retinoic acid (RA), a potent inducer of neural222 Cell Stem Cell 2, 219–229, March 2008 ª2008 Elsevier Inc.differentiation (Bain et al., 1995; Bain et al., 1996). RA-treated,
control EBs expressed high levels of neural cell adhesion mole-
cule 1 (Ncam1), a marker of mature neurons, by day 10 of differ-
entiation, butNcam1 induction was suppressed in both mESmiR-1
and mESmiR-133 EBs (Figure 3C). We also examined expression
of Nestin, which is restricted largely to neural progenitor cells
and is downregulated upon further neural differentiation (Hock-
field and McKay, 1985). Nestin expression persisted beyond
day 10 in mESmiR-1 and mESmiR-133 EBs, well after its decline
in control EBs, suggesting an accumulation of neural progenitors
(Figure 3D). Suppression of endoderm or neuroectoderm differ-
entiation was not observed when an endothelial-enriched micro-
RNA, miR-126, was similarly introduced into mES cells (see
Figure S1 available online), indicating specificity of miR-1 and
miR-133 effects. These data indicate that both miR-1 and miR-
133 can curtail the differentiation of pluripotent cells into mature
neurons, even as cells are pushed toward that lineage by timed
administration of RA.
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MicroRNAs Direct Cell Fate in Embryonic Stem CellsFigure 3. Both miR-1 and miR-133 Suppress Endoderm and Neuroectoderm Differentiation in mES Cells
(A and B) qRT-PCR analysis of the endoderm markers Afp (A) or Hnf4a (B) from day 4, 6, or 10 nodal-treated EBs formed from control, mESmiR-1, or mESmiR-133
cells. Induction of Afp and Hnf4a expression normally observed during differentiation in the presence of nodal was suppressed by expression of miR-1 or miR-
133. Error bars reflect one standard deviation.
(C) qRT-PCR analysis of the neural markerNcam1 from day 4, 6, or 10 RA-treated EBs formed from control, mESmiR-1, or mESmiR-133 cells. Expression of miR-1 or
miR-133 suppressed the induction of Ncam normally observed during differentiation in the presence of RA. Error bars reflect one standard deviation.
(D) qRT-PCR analysis of the neural progenitor marker Nestin in day 4, 8, or 10 RA-treated EBs formed from control, mESmiR-1, or mESmiR-133 cells. Nestin expres-
sion declined in wild-type EBs by day 10 as neurons differentiated, but was maintained in mESmiR-1 and mESmiR-133 EBs. Error bars reflect one standard deviation.
(E) Plot comparing results from mRNA expression microarray analyses of day 10 control, mESmiR-1, and mESmiR-133 EBs. Plot shows that most genes were
coordinately regulated.
(F) Examples of genes that were coordinately regulated in mESmiR-1 and mESmiR-133 EBs compared to controls.Coordinate Dysregulation of Gene Expression
in mESmiR-1 and mESmiR-133 EBs
To more broadly assess the influence of miR-1 or miR-133 on lin-
eage specification and gene expression, we performed mRNA
expression microarray analyses on day 10 control, mESmiR-1,
and mESmiR-133 EBs. Consistent with the similar effects of miR-1
and miR-133 on repression of nonmuscle gene expression, the
vast majority of genes were coordinately regulated in mESmiR-1
and mESmiR-133 EBs (Figure 3E). Among the most highly downre-
gulated genes in both the mESmiR-1 and mESmiR-133 EBs were the
early endoderm markers, Afp and Hnf4a, consistent with our
qRT-PCR results from EBs treated with nodal (Figure 3F).
Expression of other genes normally enriched in endodermal
structures, such as those encoding apolipoproteins, was also
downregulated in both mESmiR-1 and mESmiR-133 EBs (Figure 3F).
These results support the idea that miR-1 and miR-133 can
suppress endoderm specification and differentiation.
Among the most highly upregulated genes in both mESmiR-1
and mESmiR-133 EBs were those associated with neuroectoderm
specification and early neural differentiation. These included the
early neurogenic transcription factors, Neurod4, Phox2b, and
Myt1, and a number ofHox genes involved in neural specification
(Figure 3F). This is consistent with our observation of persistent
Nestin expression in mESmiR-1- and mESmiR-133-derived EBs
and the apparent disruption of late-stage neuronal differentiation
by these miRNAs.
A number of mesodermal genes were also commonly dysreg-
ulated in both mESmiR-1 and mESmiR-133 EBs (Figure 3F).
Runx2 and Twist1, which are highly expressed in developingbone (Ducy et al., 1997; Bialek et al., 2004), were both upregu-
lated, further supporting our conclusion that mesoderm specifi-
cation is increased in miR-1- or miR-133-expressing EBs. How-
ever, a number of genes encoding sarcomeric proteins found in
differentiated muscle cells were decreased in both mESmiR-1 and
mESmiR-133 EBs. The mechanism for diminished sarcomeric
gene expression in EBs may differ in the two cells lines: meso-
dermal progenitors in the mESmiR-133 EBs likely fail to differenti-
ate into muscle, remaining in the progenitor state, while differen-
tiating muscle cells in mESmiR-1 EBs may prematurely exit the cell
cycle, resulting in fewer cardiac cells, as was observed upon
overexpression of miR-1 in the mouse heart (Zhao et al., 2005).
Both mechanisms would result in underrepresented muscle
gene expression, and each is consistent with our current under-
standing of miR-1 and miR-133 function.
miR-1 and miR-133 Suppress Neural Differentiation
during Teratoma Formation
To examine the ability of miR-1 and miR-133 to suppress non-
mesodermal lineages in a more in vivo setting, we injected
wild-type or miRNA-expressing mES cells subcutaneously into
SCID mice and monitored their differentiation in vivo. Trans-
planted cells of each line formed teratomas in the recipients
and were analyzed 6 weeks after inoculation. Teratomas from
control, mESmiR-1, or mESmiR-133 cells included derivatives of
all three embryonic germ layers, but the control teratomas
were much more homogeneous (Figure 4). As shown by immu-
nostaining with bIII-tubulin antibodies, teratomas from control
mES cells were composed mostly of differentiated neuronsCell Stem Cell 2, 219–229, March 2008 ª2008 Elsevier Inc. 223
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or mESmiR-133 cells had far fewer differentiated neuronal cells
(Figures 4B, 4C, 4E, and 4F).
Based on our analyses of neural differentiation in EBs, we also
immunostained teratomas using an antibody to nestin. Control
teratomas were fully differentiated and contained only rare
pockets of nestin-positive neural progenitors, as expected
(Figure 4G). However, mESmiR-1 and mESmiR-133 teratomas con-
tained abundant nestin-positive cells even after 6 weeks of de-
velopment, suggesting an arrest of neural differentiation at the
progenitor stage (Figures 4H and 4I). The accumulation of nes-
tin-positive progenitors in these teratomas further supports the
idea that miR-1 and miR-133 permit specification of the ectoder-
mal lineage from pluripotent mES cells but inhibit complete dif-
ferentiation of neural progenitor cells into neurons.
We also immunostained teratomas using an antibody to
smooth muscle a-actin, a marker of smooth muscle and imma-
ture striated muscle cells (cardiac and skeletal). Consistent
with the promesodermal effects of miR-1 and miR-133 in EBs,
mESmiR-1- and mESmiR-133-derived teratomas had more cells
on average expressing smooth muscle a-actin (Figures 4K and
4L) than control (Figure 4J). High-magnification views of immu-
nostained sections demonstrate the specificity of each antibody
(Figure S2).
The Notch Ligand, Delta-like 1, Is Translationally
Repressed by miR-1
miRNAs likely function by regulating numerous pathways, but
in some cases a subset serve as the ‘‘major’’ effectors. Since
Figure 4. Differentiation of Neural Cells Is Suppressed by miR-1 or
miR-133 in Teratomas
Teratomas were generated by injecting control, mESmiR-1, or mESmiR-133 cells
into the rear flank of SCID mice. After 6 weeks, hematoxylin and eosin-stained
teratomas derived from control ES cells were strikingly homogeneous (A) and
composed mostly of bIII-tubulin-immunoreactive neural cells (D). Teratomas
from mESmiR-1 or mESmiR-133 cells were more heterogeneous (B and C) and
contained fewer bIII-tubulin-positive cells (E and F). An accumulation of nes-
tin-positive neural precursors was observed in miR-1- or miR-133-expressing
teratomas compared to control (G–I). Expression of miR-1 or miR-133 en-
hanced muscle specification, as shown by immunostaining with smooth mus-
cle a-actin antibody (J–L). Quantification of areas immunostained with each
antibody is indicated as percentages with standard deviation. Scale bars rep-
resent 2 mm.224 Cell Stem Cell 2, 219–229, March 2008 ª2008 Elsevier Inc.Notch signaling can promote neural differentiation and inhibit
muscle differentiation in ES cells (Nemir et al., 2006; Lowell
et al., 2006), which is opposite of miR-1’s effects, we hypothe-
sized that miR-1-mediated repression of Notch signaling may
contribute to the observed effects of miR-1 in mES cells. Indeed,
we had previously shown that miR-1 directly targets the Notch
ligand delta in Drosophila for repression (Kwon et al., 2005).
Three orthologs of Drosophila delta have been identified in
mice: Dll-1, Dll-3, and Dll-4. Dll-1 and Dll-4, but not Dll-3, con-
tained putative miR-1 or miR-133 binding sites in their 30 UTR.
As shown by qRT-PCR analysis, mRNA expression of Dll-1
and Dll-4 was similar in mESmiR-1 and mESmiR-133 cells and
somewhat higher than in control mES cells (Figure 5A).
Since miRNAs can block the translation of target mRNAs, we
examined Dll-1 and Dll-4 protein levels in all three mES cell lines
(Figure 5B). mESmiR-1, mESmiR-133, and control cells had similar
levels of Dll-4 by immunocytochemistry (Figure 5B) and western
analysis (data not shown). Quantitative analysis of endogenous
Dll-1 protein was not possible due to the lack of published Dll-1
antibodies that function in western blots. However, mESmiR-1
cells had consistently decreased Dll-1 protein levels by immuno-
cytochemistry despite having normal levels of Dll-1 mRNA, con-
sistent with translational inhibition of Dll-1 by miR-1. Although
a potential miR-1 binding site in the Dll-1 30 UTR has extensive,
conserved sequence matching (Figure S3A) and is present in
an accessible region with little secondary structure (data not
shown), repression through this site was not transferable to the
luciferase 30 UTR in the surrogate assay commonly employed
to test specific binding sites (Figure S3B). However, miR-1
potently repressed protein, but not mRNA expression of an epi-
tope-tagged Dll-1 containing the full 30 UTR in a dose-dependent
manner, indicating translational inhibition of Dll-1 in mammalian
cells (Figure 5C).
Dll-1 Knockdown in mES Cells Promotes Cardiac
Mesoderm and Suppresses Nonmesoderm Gene
Expression
To determine whether downregulation of Dll-1 protein by miR-1
could account for a subset of the effects of miR-1 on cell lineage
decisions, we used short hairpin RNA (shRNA) constructs di-
rected against distinct regions of Dll-1 to generate two different
Dll-1shRNA cell lines (Dll-1shRNA-1 and Dll-1shRNA-2). The Dll-1
mRNA level was about 62% lower in Dll-1shRNA-1 cells and
40% lower in Dll-1shRNA-2 cells than in a control line expressing
a scrambled shRNA construct (Figure 5D). Oct3/4 levels and
cell morphology were unaltered (data not shown). EBs formed
from Dll-1shRNA cells had a much greater propensity toward car-
diomyocyte differentiation and formed beating cardiomyocytes
earlier than control EBs (Figure 5E). By day 12 of differentiation,
89% of EBs formed from Dll-1shRNA-1 cells and 97% of EBs from
Dll-1shRNA-2 cells contained beating cardiomyocytes compared
to 48% of Dll-1control EBs. Nkx2.5 expression, marking cardiac
progenitors, was also more highly induced in Dll-1shRNA than in
control EBs (Figure 5F), as were Nkx2.5-GFP-positive cells
(data not shown). In addition, Myogenin expression was higher
in Dll-1shRNA EBs compared to controls (Figure 5F). Although
the effect of Dll-1 knockdown on Nkx2.5 and myogenin expres-
sion was not as robust as miR-1 expression, the trends were
similar. These results indicate that depletion of Dll-1 increases
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tively Regulated by miR-1 in mES Cells,
and Knockdown of Dll-1 Expression Pro-
motes Cardiac Mesoderm and Suppresses
Nonmesodermal Gene Expression
(A) Dll-1 and Dll-4 mRNA levels, assessed by qRT-
PCR, were higher in mESmiR-1 and mESmiR-133
cells than in controls. Error bars reflect one stan-
dard deviation.
(B) Immunostaining with Dll-4 or Dll-1 antibody
showed equivalent Dll-4 protein levels in mESmiR-1,
mESmiR-133 cells, and control mES cells; Dll-1 pro-
tein levels were lower in mESmiR-1 cells and higher
in mESmiR-133 cells than in wild-type mES cells.
(C) miR-1 expression caused a dose-dependent
decrease in epitope (V5)-tagged Dll-1 protein
levels by western blot without affecting RNA ex-
pression of Dll-1 assessed by qRT-PCR (graph).
Gapdh protein levels reflect equal loading of pro-
tein. Error bars reflect one standard deviation.
(D) Dll-1 mRNA levels, assessed by qRT-PCR,
were 62% and 40% lower in response to two dis-
tinct short hairpin RNAs targeting Dll-1 mRNA
(Dll-1shRNA-1 and Dll-1shRNA-2) than in a control
cell line. Error bars reflect one standard deviation.
(E) EBs formed from Dll-1control, Dll-1shRNA-1, and
Dll-1shRNA-2 ES cells were scored for beating cardi-
omyocytes on days 8, 10, and 12 of differentiation.
Beating cardiomyocytes appeared earlier and
were more numerous in EBs from Dll-1shRNA cell
lines than in EBs from the control line. Error bars re-
flect one standard deviation.
(F) qRT-PCR analyses of Nkx2.5, Myogenin, Afp,
and Nestin expression in EBs generated from Dll-
1control, Dll-1shRNA-1, and Dll-1shRNA-2 ES cells.
Knocking down Dll-1 increased Myogenin expres-
sion, decreased Afp expression, and sustained
Nestin expression compared to controls, relative
toEScells.Errorbars reflect one standard deviation.muscle differentiation from mES cells and suggest that miR-1
may promote cardiac differentiation, in part, by downregulating
Dll-1 protein.
We also performed qRT-PCR analyses on EBs formed from
Dll-1shRNA cell lines to determine if suppression of ectodermal
and endodermal lineages by miR-1 might also involve Dll-1
downregulation. Expression of the endoderm markers Afp
(Figure 5F) and Hnf4a (data not shown) was lower in Dll-1shRNA
EBs than in Dll-1control EBs. Moreover, expression of Nestin,
which decreased between days 10 and 12 as neurons differenti-
ated in Dll-1control EBs, was increased during this period in both
lines of Dll-1shRNA EBs (Figure 5F). Thus, loss of Dll-1 also re-
presses endoderm differentiation and results in persistence of
neural progenitor gene expression.
Effects of miR-1 or miR-133 in Human ES Cells
Human ES (hES) cells often behave differently from mES cells. To
investigate whether miR-1 or miR-133 function similarly in the
two cell types, we infected the H9 hES cell line with the same
lentiviruses encoding either miR-1 or miR-133. Expression was
verified by qRT-PCR (Figure 6A). The resulting hESmiR-1 and
hESmiR-133 cell lines were differentiated as EBs in suspension
and collected on days 4, 6, and 8. NKX2.5 expression was
detectable by qRT-PCR in control human EBs by day 6 anddecreased overall by day 8 (Figure 6B). As in the mouse EBs,
hESmiR-1 EBs had higher levels of NKX2.5 expression than con-
trols, while hESmiR-133 EBs failed to induceNKX2.5 expression to
the levels observed in controls (Figure 6B). Consistent with this
finding, the percentage of hESmiR-1 EBs with beating cardiac
cells on day 18 of differentiation was more than 3-fold higher
than in wild-type EBs, while hESmiR-133 EBs did not display en-
hanced cardiomyocyte formation (Figure 6C). Thus, regulation
of cardiac differentiation by miR-1 and miR-133 appears to be
grossly similar in hES and mES cells.
To examine the effects of miR-1 or miR-133 expression on
neuroectoderm differentiation in hES cells, we also immuno-
stained day 18 control, hESmiR-1, and hESmiR-133 EBs with anti-
bodies recognizing nestin or bIII-tubulin (Figure 6D). Like
miRNA-expressing mouse EBs, hESmiR-1 and hESmiR-133 EBs ac-
cumulated more nestin-positive progenitors than control human
EBs. As in our mouse ES cell studies, there were fewer bIII-tubu-
lin-positive neural cells in hESmiR-133 EBs compared to controls,
although this effect was not consistently observed in hESmiR-1
cells. These results demonstrate that the muscle-specific
miRNAs miR-1 and miR-133 have similar, but unique, effects
on the differentiation of hES and mES cells and suggest that
miRNAs may be useful for coaxing and repressing differentiation
of human or mouse ES cells into particular lineages.Cell Stem Cell 2, 219–229, March 2008 ª2008 Elsevier Inc. 225
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This study shows that miR-1 can promote differentiation of both
mouse and human ES cells into the cardiac lineage, while miR-
133, which is normally coexpressed with miR-1 in developing
muscle, blocks differentiation of myogenic precursors. Both
miRNAs enhanced mesoderm specification and suppressed
the differentiation of ES cells into neuroectoderm or endoderm
within EBs or teratomas. miR-1 expression resulted in transla-
tional repression of Dll-1, a mammalian ortholog of delta, and re-
ducing the level of Dll-1 expression in mES cells using shRNAs
caused similar cell fate trends as miR-1 expression.
The onset of miR-1 and miR-133 expression in mES cells oc-
curred just as mesoderm is becoming specified at day 4, consis-
tent with the early twist-dependent expression ofmiR-1 through-
out Drosophila mesoderm, preceding mef2 expression (Kwon
et al., 2005; Sokol and Ambros, 2005). The ability of miR-1 and
miR-133 to promote early mesoderm gene expression when
misexpressed suggests that this early onset in ES cells may pro-
mote mesoderm lineages. Strikingly, further differentiation of
mesoderm into the muscle lineage was promoted by miR-1 but
inhibited by miR-133. This is similar to in vivo observations
(Zhao et al., 2005; Chen et al., 2006).
The findings in SRF/ ES cells that do not express miR-1 or
miR-133 provide important data that compliment the gain-of-
function studies. SRF/ cells are known to have a block of final
muscle differentiation (Weinhold et al., 2000), but the persis-
tence of Bry expression, indicative of an arrest of early mesoder-
mal progenitors, had not been noted. This observation allowed
us to determine whether loss of miR-1/miR-133 transcription
in SRF/ cells might play a causative role in this interesting de-
velopmental block. The ability of miR-1 to rescue the further dif-
ferentiation of mesodermal progenitors suggests that it can
push arrested mesoderm in SRF/ ES cells past the stage
of Bry expression, although it did not induce sarcomeric gene
expression.
Unexpectedly, miR-1 and miR-133 potently repressed endo-
derm and neuroectoderm gene expression. This repression
was observed during in vitro differentiation experiments, despite
the presence of potent inducers of each lineage, and during ter-
atoma formation in vivo. In contrast to their roles during muscle
differentiation, miR-1 and miR-133 functioned in concert to re-
press nonmuscle gene expression, suggesting that they may
have many common targets, although competitive increases in
mesoderm specification may account for some of the observed
alternative lineage suppression. Gene expression analyses of ES
cells expressing miR-1 and miR-133 also suggested that the two
microRNAs regulate many pathways in common. To our knowl-
edge, this is the first example in which miR-1 and miR-133 func-
tion in a parallel rather than opposing fashion, consistent with
their bicistronic derivation. Nonmuscle gene expression was
not detected in miR-1-2 null mouse hearts (data not shown).
However, conclusively determining whether miR-1 is required
to repress nonmuscle gene expression in vivo awaits the crea-
tion of compound miR-1-1 and miR-1-2 knockout mice.
The combined effects of the miRNAs in regulating mesoderm
differentiation and preventing endoderm and neuroectoderm dif-
ferentiation reflect a novel but elegant mechanism for controlling
lineage decisions (Figure 7). By initiating the expression of spe-
cific miRNAs, a cell might promote active clearance of tran-
scripts that it has ‘‘outgrown’’ and expedite further differentia-
tion. The repression of undesired gene expression may also be
useful in efforts to differentiate and utilize ES cells for therapeutic
purposes, as strict control of lineage potential is of utmost con-
cern to avoid tumor formation and introduction of harmful cell
types.
Several targets for miR-1 and some for miR-133 have been de-
scribed, and scores more have been predicted but not validated.
Therefore, it is likely that these miRNAs control cell-fate deci-
sions by regulating numerous genes and pathways. miR-1 regu-
lated the translation of Dll-1 protein, thereby negatively influenc-
ing Notch signaling, consistent with the observation that miR-1
negatively regulates Notch signaling by targeting delta in Dro-
sophila. Specific knockdown of Dll-1 caused cell-fate trends
similar to those caused by miR-1 expression, although combina-
torial targeting of multiple mRNAs likely results in the full effect of
miR-1. Consistent with the effects of miR-1 expression and Dll-1
knockdown, recent reports indicate that Notch1 inhibition pro-
motes cardiac differentiation and that stimulation of the Notch
pathway positively regulates neuronal differentiation (Nemir
et al., 2006; Lowell et al., 2006). Thus, despite the many path-
ways likely repressed by miR-1, our findings suggest that
Figure 6. Effects of miR-1 or miR-133 Expres-
sion in hES Cells
(A) Lentivirus-mediated expression of miR-1 or miR-
133 in human ES (hES) cells was verified by qRT-PCR.
(B) NKX2.5 mRNA expression assessed by qRT-PCR
in hEBs collected on days 4, 6, and 8. Overexpression
of miR-1 in hES cells increased NKX2.5 expression
compared to wild-type, while miR-133 expression led
to decreased NKX2.5 induction. Error bars reflect one
standard deviation.
(C) Human EBs were scored for beating on day 18 of
differentiation. Expression of miR-1 increased the
number of beating human EBs, while expression of
miR-133 did not.
(D) Day 18 human EBs were immunostained with anti-
bodies to nestin or bIII-tubulin.226 Cell Stem Cell 2, 219–229, March 2008 ª2008 Elsevier Inc.
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mechanisms by which miR-1 influences cell fate decisions (Fig-
ure 7). Whether miR-133 also functions by regulating other com-
ponents of Notch signaling or whether it targets independent
pathways remains to be determined. It will be interesting to
determine if miR-1 or miR-133 also control other regulators of
cardiac progenitors such as those involved in canonical Wnt
signaling (Kwon et al., 2007).
In summary, our results indicate that the muscle-specific
miRNAs miR-1 and miR-133 act comparably during mES and
hES differentiation to promote mesoderm differentiation while
suppressing gene expression of alternative lineages. Our results
also suggest that miRNAs may offer a means to direct the differ-
entiation of ES cells into desired fates and inhibit the formation
of undesired lineages.
EXPERIMENTAL PROCEDURES
Mouse ES Cell Culture and Flow Cytometry
The mouse E14 ES cell line was maintained as a monolayer in medium supple-
mented with 10% fetal bovine serum, LIF-conditioned medium, pyruvate, glu-
tamine, and b-mercaptoethanol in gelatin-coated tissue-culture plates and
passaged with trypsin. Cells were differentiated by the hanging drop method.
Briefly, cells were trypsinized and resuspended at 25,000 cells/ml in differen-
tiation medium (20% fetal bovine serum, pyruvate, glutamine, and b-mercap-
toethanol). Droplets (20 ml) were transferred to each well of a 96-well v-bottom
tissue culture plate, which was then inverted. After 2 days of incubation at
37C, the plates were turned upright, and 200 ml of differentiation medium
was added to each well. For neuroectodermal or endodermal induction, 0.5
mM retinoic acid (Sigma) or 50 ng/ml recombinant nodal (R&D Systems), re-
spectively, was added to the wells 96 hr after formation of the hanging drops.
The medium was changed every 2 days. The b-myosin heavy-chain-GFP E14
cells were a gift of W. Tingley and R. Shaw. For flow cytometry studies, EBs
were dissociated with trypsin and passed through a nylon cell strainer.
Flk-1+ cells were labeled with a PE-conjugated Flk-1 antibody (BD PharMin-
gen) and a Becton Dickinson (Franklin Lakes, NJ) FACS Diva flow cytometer,
and cell sorter was used for detecting and sorting Flk-1+, Nkx2.5-GFP+, or
bMHC-GFP+ cells.
Figure 7. Model of miR-1/miR-133 Effects during ES Cell Differenti-
ation
miR-1 and miR-133 promotion of mesoderm and inhibition of endoderm and
ectoderm differentiation at specific stages are indicated. Opposing effects
of the two miRNAs in later steps of muscle differentiation are also shown.
miR-1 inhibition of Dll-1 translation, along with yet unknown targets, likely con-
tribute to some of the observed effects of miR-1.miRNA and mRNA Expression Microarray Analyses
ES cells or EBs were harvested in Trizol (Invitrogen) for total RNA isolation. For
mRNA expression microarray analysis, 1 mg total RNA was labeled and hybrid-
ized to a mouse mRNA expression microarray (Affymetrix). Gene expression
values were obtained from Affymetrix CEL files using the GC-RMA package
from Bioconductor (Dudoit et al., 2003; Wu and Irizarry, 2004). To identify tran-
scripts differing in mean expression across the three experimental groups
(mESwt, mESmiR-1, and mESmiR-133 EBs), p values were calculated by permu-
tation test with the F-statistic function from the multitest package of Biocon-
ductor (Dudoit et al., 2003) and a t test comparing each miRNA-expressing
group to wild-type EBs. Fold changes in transcript levels were calculated
from the mean log2 expression values versus the mean of control EBs.
For miRNA expression microarray, 100 ng of total RNA from each sample
was labeled with Cy3 or Cy5 using miRCURY LNA microRNA Power labeling
kit (Exiqon) and then hybridized to miRCURY LNA arrays (Exiqon). Hybridiza-
tion quality was assessed with Bioconductor marray package, and log2 ratios
of Cy5 to Cy3 signals were calculated with limma package.
Quantitative RT-PCR
ES cells or EBs were harvested in Trizol (Invitrogen) for total RNA isolation. For
mRNA qRT-PCR, 2 mg of total RNA from each sample was reversed tran-
scribed with Superscript III (Invitrogen). One-sixteenth of the reverse transcrip-
tion reaction was used for subsequent PCRs, which were performed in dupli-
cate on an ABI 7900HT instrument (Applied Biosystems) using Taqman primer
probe sets (Applied Biosystems) for each gene of interest and a GAPDH en-
dogenous control primer probe set for normalization. Each qRT-PCR was per-
formed on at least three different experimental samples; representative results
are shown as fold expression relative to undifferentiated ES cells unless other-
wise stated. Error bars reflect one standard deviation from the mean of tech-
nical replicates.
miRNA qRT-PCR was performed with miRNA Taqman Expression Assays
(Applied Biosystems) and the miRNA Reverse Transcription kit (Applied Bio-
systems). For each miRNA analyzed, 10 ng of total RNA was reverse tran-
scribed with a miRNA-specific primer. A ubiquitous miRNA, miR-16, was
used as the endogenous control. Each qRT-PCR was performed on at least
three different experimental samples; representative results are shown as
fold expression relative to undifferentiated ES cells unless otherwise noted. Er-
ror bars indicate one standard deviation from the mean of technical replicates.
Lentiviral Production and ES Cell Infection
Lentiviruses for miRNA expression were generated with the ViraPower Promo-
terless Lentiviral Gateway Expression System with MultiSite Gateway Tech-
nology (Invitrogen). The EF-1a promoter was recombined into the pLenti vec-
tor upstream of a cassette containing either miR-1 or miR-133 pre-miRNA
sequence with an additional 100 nucleotides flanking each end, which was
cloned by PCR from a bacterial artificial chromosome containing the mouse
genomic miR-1-2 or miR-133a-1 sequences. Details of virus production and
introduction into ES cells can be found in the Supplemental Experimental
Procedures.
Teratoma Formation
Teratomas were formed by subcutaneous injection of approximately 1 3 106
control or miRNA-expressing mES cells into the rear flank of 8-week-old
male SCID mice (n = 10 mice per cell line). Transplanted cells of each
line formed teratomas in the recipients and were analyzed 6 weeks after
inoculation.
Immunostaining
For immunocytochemistry studies, ES cells were plated on gelatinized cover-
slips and allowed to settle, rinsed with PBS, fixed in 4% paraformaldehyde for
1 hr at room temperature with shaking, and stored in PBS at 4C. The fixed
cells were rinsed in PBS, blocked in blocking solution (1% bovine serum albu-
min, 1% Tween-20, and PBS) for 30 min at room temperature and incubated in
primary antibody in a humidified chamber for 1 hr at room temperature. The
antibodies were diluted in blocking buffer as follows: Dll-1, 1:100 (AbCam,
ab10554); Jag-1, 1:100 (AbCam, ab7771); Dll-4, 1:50 (AbCam, ab7280). After
washing in PBS, the cells were incubated for 1 hr with FITC-conjugated sec-
ondary antibodies (1:200) at room temperature in a darkened chamber, rinsedCell Stem Cell 2, 219–229, March 2008 ª2008 Elsevier Inc. 227
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Laboratories).
For immunohistochemical studies, teratomas were submerged in CPT (Sa-
kuro), flash frozen in liquid nitrogen, and sectioned. Details of immunostaining
and antibodies are in the Supplemental Experimental Procedures.
For EB immunohistochemistry, EBs were fixed in 4% paraformaldehyde,
blocked in 5% goat serum, and incubated overnight in bIII-tubulin antibody
(1:100; Chemicon, CBL412). The following day, EBs were rinsed, placed in rho-
damine-conjugated anti-mouse IgG diluted 1:400 for 2 hr, rinsed, mounted
with Vectashield containing DAPI (Vector Laboratories), and visualized.
Dll-1 Knockdown
mES cells were infected with lentiviral constructs encoding shRNAs against
mouse Dll-1 or a control shRNA (Sigma). After transduction and 2 days of re-
covery, infected mES cells were selected for 7 days with 1 mg/ml puromycin.
Colonies were isolated, expanded, and assayed for Dll-1 knockdown com-
pared to control-infected mES cells by qRT-PCR. The pluripotency of the re-
sulting cell lines was assessed by measuring the proliferation rate and Oct3/4
expression and comparing the value to those of uninfected mES cells. Only
lines that maintained normal levels of Oct3/4 expression and normal prolifera-
tion rates were used for further study.
miR-1 Target Analyses
For luciferase assays or transient expression analyses, Cos-1 cells in 12-well
plates were transfected with Lipofectamine 2000 (Invitrogen). For luciferase
assays, a luciferase expression construct containing the 30 UTR of mouse
Dll-1 (50 ng) was cotransfected alone or with miR-1 or miR-133 expression
constructs (300 ng) and a LacZ expression construct. Empty expression plas-
mid was used to normalize the total DNA mass. After 24 hr, cells were har-
vested and the luciferase assays were performed with Luciferase Assay Kit
(Promega). b-galactosidase assays were also performed and the results
were used to normalize for transfection efficiency. For transient expression
analyses, a Dll-1 expression construct lacking Dll-1-derived 50 UTR sequence
elements, but with the full mouse Dll-1 30 UTR, and an n-terminal V5 epitope
tag (75 ng) was cotransfected with increasing amounts of miR-1 expression
construct (0 ng, 350 ng, or 700 ng). Empty expression vector was included
to ensure equal DNA mass in each condition. After 24 hr, cells were harvested
in modified RIPA buffer or Trizol (Invitrogen). Western analyses to detect V5-
tagged Dll-1 protein were performed with HRP-conjugated V5 antibody diluted
1:1500 (Invitrogen).
Human ES Cell Culture
The human ES cell line, H9 (WiCell), was maintained on mouse embryonic
feeder cells in proliferation medium consisting of Knockout DMEM (GIBCO)
supplemented with 20% Knockout serum replacement (GIBCO), pyruvate,
glutamine, b-mercaptoethanol and human basic fibroblast growth factor. De-
tails of hES cell differentiation and immunostaining can be found in Supple-
mental Experimental Procedures.
SUPPLEMENTAL DATA
The Supplemental Data include three figures and Supplemental Experimental
Procedures and can be found with this article online at http://www.
cellstemcell.com/cgi/content/full/2/3/219/DC1/.
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